Zimbuck – Your Market. Your Community.
🚨 BREAKING: PepGen stock more than doubles on muscle-disease data

PepGen (Nasdaq: PEPG) shares more than doubled on Tuesday after Phase 2 data for its myotonic dystrophy type 1 (DM1) drug PGN-EDODM1 wowed analysts.
• The 10 mg/kg cohort showed a mean splicing correction of 46.5% — the highest reported to date in a multiple-dose study
• 5 of 6 participants topped 20% splicing improvement, and 4 topped 50%, at Week 13
• Hand opening time, grip strength and mobility measures also improved, with no discontinuations or serious adverse events
• Guggenheim analysts called the result potentially the new benchmark for splicing; cash stood at $104.8M at September 30

#PepGen #PEPG #Biotech #Stocks #Investing #Earnings
Like
Love
12
234 Views